GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » 5-Year Yield-on-Cost %

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 22, 2024)


View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) 5-Year Yield-on-Cost %?

ImmuneOnco Biopharmaceuticals (Shanghai)'s yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for ImmuneOnco Biopharmaceuticals (Shanghai)'s 5-Year Yield-on-Cost % or its related term are showing as below:



HKSE:01541's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.92
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s 5-Year Yield-on-Cost %

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuneOnco Biopharmaceuticals (Shanghai)'s 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s 5-Year Yield-on-Cost % falls into.



ImmuneOnco Biopharmaceuticals (Shanghai) 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of ImmuneOnco Biopharmaceuticals (Shanghai) is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


ImmuneOnco Biopharmaceuticals (Shanghai) 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Traded in Other Exchanges
N/A
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Executives
Gba Fund Investment Limited 2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Halo Biomedical Lp 2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited 2101 Beneficial owner
Halo Biomedical Investment I Limited 2201 Interest of corporation controlled by you
Tian Wenzhi 2501 Other
Lav Immon Hong Kong Limited 2101 Beneficial owner
Greater Bay Area Homeland Investments Limited 2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited 2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited 2101 Beneficial owner
Lav Gp V, L.p. 2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p. 2201 Interest of corporation controlled by you
Shi Yi 2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines